|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.5985 - 0.5985|
|52 Week Range||0.4798 - 0.8940|
|Beta (5Y Monthly)||1.21|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Mar. 08, 2016|
|1y Target Est||N/A|
Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the official launch of its online e-commerce platform and web site at www.Canntab.ca.
The agreement is anticipated to contribute to correcting the opioid crisis in Canada and serve as a foundation for both companies to potentially expand into new verticals in the futureLevitee Labs and Canntab Therapeutics have executed a services agreement resulting in Levitee Labs informing patients about the Canntab portfolio of therapeuticsLevitee Labs will offer the entire Canntab product lineup throughout all its clinics and pharmacies in Western Canada VANCOUVER, British Columbia, Jan. 10,
Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to provide an update on its recent product deliveries for Ontario and Australia.